Voice biomarker platform Sonde Well being raises $19.25M to unfold entry to psychological well being monitoring and past

Voice analy­sis plat­form Sonde Health rais­es $19.25M (Mobi­Well being­Information):

AI-enabled voice tech­nol­o­gy plat­type Sonde Well being introduced it raised $19.25 mil­lion in a Collection B fund­ing spherical led by Half­ners Make investments­ment, deliver­ing its whole elevate to $35.25 mil­lion … Sonde Well being makes use of patent­ed voice tech­nol­o­gy to detect var­i­ous well being con­di­tions from bio­mark­ers in a per­son­’s voice, includ­ing ana­lyz­ing res­pi­ra­to­ry match­ness and detect­ing depres­sion and anxiousness.

The fund­ing will assist construct out the com­pa­ny’s tech­nol­o­gy to detect addi­tion­al well being con­di­tions, broaden its cur­hire res­pi­ra­to­ry and males­tal health-mon­i­tor­ing tech­nolo­gies, and dri­ve glob­al com­mer­cial development.

“Dig­i­tal bio­mark­ers are becom­ing a essential­keep in well being­care. At the moment’s well being­care com­pa­nies are actual­iz­ing how vocal bio­mark­ers can have interaction peo­ple ear­li­er of their well being. The info and insights present in voice can pow­er well being mon­i­tor­ing and affected person strat­i­fi­ca­tion so points can grow to be appar­ent properly earlier than a value­ly med­ical occasion happens,” David Liu, CEO of Sonde Well being, stated in a state­ment. “With voice and any lis­ten­ing machine, acces­si­ble and effec­tive well being mon­i­tor­ing might be made avail­capable of the most important­i­ty of the world.”

The Announcement:

Sonde Health Rais­es $19.25 Mil­lion Series B to Build the Next Gen­er­a­tion of Voice-Based Health Mon­i­tor­ing (press launch):

Sonde Well being, a well being tech­nol­o­gy com­pa­ny com­mit­ted to deliver­ing acces­si­ble well being mon­i­tor­ing to each­one, has raised a $19.25 mil­lion Collection B make investments­ment spherical … The com­pa­ny has raised $35.25 mil­lion in whole and can use the fund­ing to dri­ve its glob­al com­mer­cial development, deep­en its res­pi­ra­to­ry and males­tal well being mon­i­tor­ing tech­nolo­gies, and construct capa­bil­i­ties for addi­tion­al well being circumstances.

Sonde licens­es its plat­type to cus­tomers glob­al­ly in two methods:

Well being Checks

• Res­pi­ra­to­ry Match­ness: Sonde’s plat­type can detect and mon­i­tor res­pi­ra­to­ry well being con­di­tions, like asth­ma, from 6 sec­onds of voice. Sufferers are engag­ing with Sonde’s res­pi­ra­to­ry match­ness well being checks 2+ instances per week.
• Males­tal Match­ness: Sonde’s plat­type can detect and mon­i­tor evi­dence of depres­sion and anx­i­ety from 30 sec­onds of voice. Sufferers are engag­ing with Sonde’s males­tal match­ness well being checks 3+ instances per week.

Vocal Bio­mark­er Improvement

• MCI, COPD, Gen­er­al Well being: Sonde is devel­op­ing nov­el vocal bio­mark­ers utilizing its professional­pri­etary “research-build-val­i­da­tion” technique­ol­o­gy with clin­i­cal companions.

… GN Group will inte­grate Sonde’s Males­tal Match­ness vocal bio­mark­er into its hear­ing prod­ucts. The com­pa­ny is already work­ing with Sonde to devel­op an MCI vocal bio­mark­er. Qual­comm, which has already inte­grat­ed Sonde’s vocal bio­mark­ers into its cellular machine chipsets, has lengthen­ed the rela­tion­ship to incorporate its put on­in a position chipsets. Koye Phar­ma­ceu­ti­cals, which had already engaged Sonde to devel­op a COPD vocal bio­mark­er, has broaden­ed the half­ner­ship to devel­op a nov­el males­tal well being vocal bio­mark­er for deploy­ment in India.

Information in Context: